AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Biopharma adds three clinical-stage oncology drug candidates to its pipeline.
2004 FEB 5 - (NewsRx.com & NewsRx.net) -- Keryx Biopharmaceuticals, Inc., (KERX) has entered into an agreement to acquire ACCESS Oncology, Inc., a privately held, cancer-focused biotechnology company.
The acquired drug portfolio includes three clinical stage compounds, to be designated as KRX-0401, KRX-0402, and KRX-0403.
KRX-0401 is a novel, first-in-class, oral AKT-inhibitor that has demonstrated single agent antitumor activity in phase I studies and is currently in nine phase II single agent clinical trials in six tumor types, including breast, prostate, melanoma, pancreatic, sarcoma, and head and neck cancer, being conducted by the National Cancer Institute (NCI) under a collaborative research and development agreement (CRADA) arrangement.
Activation of the AKT pathway is believed to play an important role in cell survival and cell proliferation. KRX-0401 is a potent inhibitor of AKT activation and is believed to be the only AKT inhibitor in clinical development primarily for the treatment of cancer. Additionally, KRX-0401 has been shown to significantly inhibit additional signal transduction pathways including MAPK and JNK, adding to its anticancer effects. Moreover, preclinical data generated suggests significant synergy with other anticancer therapies. Accordingly, in 2004, Keryx plans ...
- Data from KRX-0401 single-agent soft-tissue sarcoma study presented at meeting.
- Magazine article from: Women's Health Weekly October 28, 2004 700+ words
...tolerability and potential efficacy of KRX-0401 (perifosine) in the...phase II, multicenter study of KRX-0401, 23 patients with advanced...the earlier phase I program. KRX-0401 was also shown to be...article was prepared by Women's Health Weekly editors from staff and other...
- Keryx Expands Study Program for Lead Compound, KRX-101.
- Press release article from: PR Newswire September 17, 2003 700+ words
...Open Access Research) Program Collaboration for KRX-101 Esteemed Researcher to explore impact of KRX-101 on development and progression of Diabetes...Biopharmaceuticals, Inc. (Nasdaq: KERX; London AIM: KRX) announced today that, in connection with its...
- Additional Data on Mechanism of Action of KRX-0401 (Perifosine) Published in...
- Press release article from: PR Newswire February 5, 2004 700+ words
...Biopharmaceuticals (Nasdaq: KERX; London AIM: KRX) notes the recent publication of pre-clinical data elucidating the mechanism by which KRX-0401 (Perifosine) activates p21(waf1...Association for Cancer Research (AACR). KRX-0401 is the lead cancer compound being...
- CME Group, KRX Announce After-hours Access to KOSPI 200 Futures on CME Globex.
- Press release article from: PR Newswire November 16, 2009 700+ words
...marketplace, and the Korea Exchange Inc. (KRX), a premier capital marketplace for Northeast...trading platform by routing orders through KRX Unified System for Global (USG) trading...Chicago Mercantile Exchange (CME) and KRX also indicated their commitment to pursue...
- Keryx Biopharmaceuticals, Inc. Initiates First Chemotherapy Combination Study...
- Press release article from: PR Newswire August 4, 2004 700+ words
...sponsored chemotherapy combination study for KRX-0401 (Perifosine), a novel, oral...This multi-center trial will evaluate KRX-0401 in combination with Gemcitabine...three continuous daily dosing regimes of KRX-0401 (50mg, 100mg and 150mg/day...
- Keryx Biopharmaceuticals, Inc. Commences Phase II, Multi-Center Study of...
- Press release article from: PR Newswire January 3, 2006 700+ words
...sponsored clinical program to evaluate KRX-0401 (perifosine) as a treatment for...the Safety and Efficacy of Perifosine [KRX-0401] Alone and in Combination with Dexamethasone...refractory multiple myeloma will be treated with KRX-0401 (150 mg oral daily dose) to assess...
- Keryx Biopharmaceuticals Launches SOAR Program to Expand Study of KRX-101...
- Press release article from: PR Newswire August 12, 2003 700+ words
...Biopharmaceuticals, Inc. (Nasdaq: KERX; London AIM: KRX) announced the initiation of a program...additional potential clinical applications of KRX-101 (sulodexide), the Company's lead...complement and support our lead program for KRX-101 in the treatment of diabetic nephropathy...
- Keryx Provides Update on KRX-123, Its Drug Candidate for Hormone Resistant...
- Press release article from: PR Newswire December 17, 2002 700+ words
...Biopharmaceuticals, Inc. (Nasdaq: KERX; AIM: KRX), a drug discovery company focusing on...FDA to discuss the clinical development of KRX-123, a peptide drug candidate for the...formulation strategy for the clinical trials of KRX-123. As the company has previously stated...